At a glance
ClinicalIndex Comparison Record- ✓Histologically or cytologically confirmed invasive breast cancer
- ✓Operable breast cancer ≥2 cm, no distant metastatic disease (inflammatory breast cancer permitted)
- ✓Hormone receptor-positive (ER>1% or PR>1%), HER2-negative per ASCO CAP guidelines 2013
- ✓Age ≥18 years
- ✕Prior pembrolizumab or any anti-PD-1, anti-PD-L1, or anti-PD-L2 therapy
- ✕History or evidence of active, non-infectious pneumonitis or interstitial lung disease
- ✕Uncontrolled intercurrent illness including uncontrolled hypertension, unstable angina, uncontrolled cardiac arrhythmia, CHF (NYHA Class III-IV), active ischemic heart disease, MI within 6 months, uncontrolled diabetes, chronic liver/renal disease, or severe malnutrition
- ✕Active autoimmune disease or documented history of autoimmune disease/syndrome requiring systemic steroids or immunosuppressive agents
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer
In Brief
A Phase 1 clinical trial evaluating Pembrolizumab, Nab-Paclitaxel, and 1 other intervention for Breast Cancer. Completed, enrolled 32 participants across 1 site.
Detailed Summary
This research study is exploring chemotherapy in combination with immunotherapy (a therapy that uses the body's own immune system to control cancer) as a possible treatment for hormone receptor positive breast cancer. The interventions involved in this study are: * Pembrolizumab (MK-3475; Keytruda™) * Nab-Paclitaxel (Abraxane
Study Details
Timeline
Interventions
Pembrolizumab will be administered in clinic every three weeks.
Nab-Paclitaxel will be administered in clinic every week.
Biopsies for research purposes will be performed at three separate timepoints during treatment.